Understanding the consequences of drug legalisation versus prohibition is important for policy. Most recently this subject has gained much political attention not only globally, but specifically in the Netherlands. This study will provide a contribution to the legalisation debate based on a microeconomic analysis of the effects of illegal markets. The research question is how to design a coherent soft drugs policy framework that maximizes social welfare within the Netherlands that precludes most historical, sociological and political debates. In particular, attention is restricted to ‘soft drugs’ better known as cannabis derived products like hashish and marijuana.
In August 2010, Mexican President Felipe Calderon declared that he would support a national debate on the issue of legalisation, reversing his previous stance on the subject. However, he underscored that he did not favour legalisation, particularly since the US and the international community maintained their prohibitionist approach. This IDPC Briefing Paper offers background information on the cannabis political debate in Mexico.
Latin America has emerged at the vanguard of efforts to promote debate on drug policy reform. For decades, Latin American governments largely followed the drug control policies and programs of Washington’s so-called war on drugs. Yet two parallel trends have resulted in a dramatic change in course: the emergence of left-wing governments that have challenged Washington’s historic patterns of unilateralism and interventionism and growing frustration with the failure of the prohibitionist drug control model put forward by the US government.
Uruguay’s senate voted today (10 December) to approve the world’s first national legal framework regulating the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes.
The Netherlands has long been considered a leader of progressive drug policy, but it is increasingly being left behind by policy innovations outside Europe. Nonetheless Dutch cities are leading the way towards more progressive and locally adapted cannabis policies. Produced as part of a the "New Approaches in Harm Reduction Policies and Practices" project, this Country Report seeks to understand the drivers of Dutch cannabis policy today, and the possibilities for its future.
This is a guide to regulating legal markets for the non-medical use of cannabis. It is for policy makers, drug policy reform advocates and affected communities all over the world, who are witnessing the question change from, 'Should we maintain cannabis prohibition?' to 'How will legal regulation work in practice?
Despite efforts by governments in Latin America, illicit drugs continue to provide one of the largest incomes for criminal organizations, enabling them to penetrate and corrupt political and social institutions.
International tensions over Uruguay’s decision to regulate the cannabis market reached new levels when Raymond Yans, president of the International Narcotics Control Board (INCB), accused Uruguay of negligence with regard to public health concerns, deliberately blocking dialogue attempts and having a "pirate attitude" towards the UN conventions. President Mujica reacted angrily, declaring that someone should "tell that guy to stop lying," while Milton Romani, ambassador to the Organisation of American States (OAS), said that Yans "should consider resigning because this is not how you treat sovereign states."
The report reviews 20 years of data from US government funded surveillance systems on government drug control spending, cannabis seizures and cannabis arrests, in order to assess the impact of enforced cannabis prohibition on cannabis potency, price and availability. The report’s findings highlight the clear failure of cannabis prohibition efforts by showing that as the United States has dramatically scaled up drug law enforcement, cannabis potency has nevertheless increased, prices have dropped, and cannabis remains widely available.
Cannabis was condemned by the 1961 Single Convention on Narcotic Drugs as a psychoactive drug with “particularly dangerous properties” and hardly any therapeutic value. Ever since, an increasing number of countries have shown discomfort with the treaty regime’s strictures through soft defections, stretching its legal flexibility to sometimes questionable limits.
Cannabis social clubs (CSC) are noncommercial organisations of users who get together to cultivate and distribute enough cannabis to meet their personal needs without having to turn to the black market. They are based on the fact that the consumption of illegal drugs has never been considered a crime under Spanish legislation. Taking advantage of this grey area, private clubs that produce cannabis for non-profit distribution solely to a closed group of adult members have existed for years.
Uruguay’s senate voted today (10 December) to approve the world’s first national legal framework regulating the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes. The historical vote is expected to inspire and spread cannabis reform initiatives around the world and to have a major impact on upcoming UN-level drug policy evaluations.
Martin Jelsma is a political scientist who has specialised in Latin America and international drugs policy. In 2005, he received the Alfred R. Lindesmith Award for Achievement in the Field of Scholarship, which stated that Jelsma "is increasingly recognized as one of, if not the, outstanding strategists in terms of how international institutions deal with drugs and drug policy."...
There is a growing recognition around the world that the prohibition of drugs is a counterproductive failure. However, a major barrier to drug law reform has been a widespread fear of the unknown—just what could a post-prohibition regime look like?
A grey area has emerged between what is legal and what is not as states struggle with how to respond to the many new synthetic compounds emerging onto the market. Of the various types of ‘Legal highs’ the seminar focused on stimulants because of the parallels with the other main drug-policy issue of the moment; i.e. the status of traditional herbal stimulants. These older discussions have been reinvigorated by: Bolivia’s efforts to de-schedule coca-leaf at UN level; the debates on the status of khat between EU States, and of kratom across Asia; and the increasing stride of legitimate cannabis use on the domestic front, as in for example Spain.
The Expert Dialogue took place in the Miramar Palace in San Sebastian and was hosted by the municipal authorities of the city. Dialogue focused on examining some regulation models currently being implemented.
In 1976 the Netherlands adopted a formal written policy of non-enforcement for violations involving possession or sale of up to 30 g of cannabis. The ‘gateway theory’ has long been seen as an argument for being tough on cannabis, but interestingly, the Dutch saw that concept as a rationale for allowing retail outlets to sell small quantities. Rather than seeing an inexorable psychopharmacological link between marijuana and hard drugs, the Dutch hypothesized that the gateway mechanism reflected social and economic networks, so that separating the markets would keep cannabis users out of contact with hard-drug users and sellers.
Since first coming to public prominence at the end of 2009, legal highs have posed a major challenge to existing legal and legislative structures designed to deal with drugs. With the market in manufactured psychoactive substances like mephedrone moving faster than public policy can accommodate, this report asks whether the assumptions enshrined in the 40-year-old Misuse of Drugs Act (MDA) are still valid when applied 21st century drugs market.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate continues on the decriminalisation, or even legalisation, of drugs, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.